These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19473378)

  • 21. Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet.
    Freye E; Levy JV; Braun D
    Pain Pract; 2007 Dec; 7(4):324-31. PubMed ID: 17986159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fentanyl sublingual spray for breakthrough pain in cancer patients.
    Zeppetella G
    Pain Ther; 2013 Jun; 2(1):1-9. PubMed ID: 25135032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioid formulations: tailoring to the needs in chronic pain.
    Reder RF
    Eur J Pain; 2001; 5 Suppl A():109-11. PubMed ID: 11798229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal sufentanil for cancer-associated breakthrough pain.
    Good P; Jackson K; Brumley D; Ashby M
    Palliat Med; 2009 Jan; 23(1):54-8. PubMed ID: 19144765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial.
    Israel FJ; Parker G; Charles M; Reymond L
    J Pain Symptom Manage; 2010 Mar; 39(3):548-54. PubMed ID: 20083373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain.
    Lasheen W; Walsh D; Mahmoud F; Sarhill N; Rivera N; Davis M; Lagman R; Legrand S
    Palliat Med; 2010 Jan; 24(1):9-16. PubMed ID: 19910396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of breakthrough pain due to cancer.
    Simmonds MA
    Oncology (Williston Park); 1999 Aug; 13(8):1103-8; discussion 1110, 1113-4. PubMed ID: 10499244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent development in therapeutics for breakthrough pain.
    Davis MP
    Expert Rev Neurother; 2010 May; 10(5):757-73. PubMed ID: 20420495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.
    Ridgway D; Sopata M; Burneckis A; Jespersen L; Andersen C
    J Pain Symptom Manage; 2010 Apr; 39(4):712-20. PubMed ID: 20413058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advancement of opioid analgesia with controlled-release oxycodone.
    Levy MH
    Eur J Pain; 2001; 5 Suppl A():113-6. PubMed ID: 11798230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pain management of opioid-treated cancer patients in hospital settings in Denmark.
    Lundorff L; Peuckmann V; Sjøgren P
    Acta Anaesthesiol Scand; 2008 Jan; 52(1):137-42. PubMed ID: 18005379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.
    Geppetti P; Benemei S
    Clin Drug Investig; 2009; 29 Suppl 1():3-16. PubMed ID: 19445550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of sustained release oral morphine as a bridge in withdrawal of morphine in patients on high doses of oral immediate release morphine for cancer pain.
    Ahmed A; Khurana H; Gogia V; Mishra S; Bhatnagar S
    Am J Hosp Palliat Care; 2010 Sep; 27(6):413-5. PubMed ID: 20220200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
    Borgbjerg FM; Rosenberg J
    Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-controlled analgesia versus oral controlled-release oxycodone - are they interchangeable for acute postoperative pain after laparoscopic colorectal surgeries?
    Ho HS
    Oncology; 2008; 74 Suppl 1():61-5. PubMed ID: 18758200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy.
    Davis MP; Varga J; Dickerson D; Walsh D; LeGrand SB; Lagman R
    Support Care Cancer; 2003 Feb; 11(2):84-92. PubMed ID: 12560936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
    van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
    Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of severe non-cancer pain by oral morphine].
    Kato Y; Kato A
    Masui; 2008 Nov; 57(11):1343-50. PubMed ID: 19039960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain.
    Southworth S; Peters J; Rock A; Pavliv L
    Clin Ther; 2009 Sep; 31(9):1922-35. PubMed ID: 19843482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.